Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

long-term condition

- PMLiVE

GSK takes new-class antibiotic into phase 3 for serious infections

Could provide a much-needed option for treatment-resistant infections

Are we ready for an Alzheimer’s disease modifying treatment

Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. But if a new therapy entered the market today, would healthcare systems be ready for...

Blue Latitude Health

- PMLiVE

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

Therapy candidate was licensed in a $1bn-plus deal last year

- PMLiVE

GSK’s pivotal TB vaccine could prevent millions of deaths

Key study took place in TB-endemic regions, testing 3,500 participants

- PMLiVE

AZ’s Imfinzi combo scores in front-line lung cancer

Attempts to catch up to BMS and Merck in non-small cell lung cancer

- PMLiVE

Healthcare’s voice revolution

With the UK’s NHS unveiling a major partnership with Amazon’s Alexa, is pharma in danger of being left behind?

- PMLiVE

Provention Bio wins PRIME designation for type 1 diabetes prevention drug

Meanwhile J&J partnered Crohn's drug flops in phase 2

Roche Basel Switzerland

Roche moving closer to approval of Spark takeover; report

Antitrust authorities in both US and UK look likely to end delay

- PMLiVE

Another day, another Brexit delay – so what happens now?

Health Secretary Matt Hancock maintains UK will retain regulatory collaboration with EMA

- PMLiVE

Merus makes case for bispecific antibody in specific cancer gene fusion

Could become a potential treatment for hard-to-treat cancers

Externalities

Improving my health through your own behaviour is not easy

- PMLiVE

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Approval comes after an accelerated review of the drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links